[Immunogenicity and stability of an aluminum-free liposomal hepatitis A vaccine (Epaxal Berna)]

Schweiz Med Wochenschr. 1994 Nov 12;124(45):2053-6.
[Article in German]

Abstract

The high immunogenicity of the liposomal hepatitis A vaccine (Epaxal Berna) after a single dose and after a booster dose one year later has been confirmed in several studies with healthy adult volunteers: 95-100% and 96-100% seroconversion (> or = 20 mIE/ml) after 1 and 12 months respectively, as well as a booster effect in 100% of the cases after revaccination. The tolerability of this new, alum-free vaccine has been excellent with 6-25% local and 0-13% mild systemic reactions after a dose of 0.5 ml. Stability testing with and without detergent indicated partial internalization of the hepatitis A virions in the phospholipid bilayer of the liposome vesicles with storage. Immunization of 10 healthy adult volunteers with vaccine stored for 32 months at 4 degrees C showed, however, that the duration of storage has no influence on immunogenicity and tolerability of the vaccine.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aluminum
  • Drug Carriers
  • Drug Stability
  • Drug Storage
  • Female
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies / isolation & purification
  • Hepatovirus / immunology*
  • Humans
  • Liposomes
  • Male
  • Middle Aged
  • Time Factors
  • Vaccines, Attenuated
  • Viral Hepatitis Vaccines / administration & dosage
  • Viral Hepatitis Vaccines / immunology*

Substances

  • Drug Carriers
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis Antibodies
  • Liposomes
  • Vaccines, Attenuated
  • Viral Hepatitis Vaccines
  • Aluminum